[HTML][HTML] Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan …
P Perrone-Filardi, S Paolillo, P Agostoni… - European Journal of …, 2022 - Elsevier
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position …
P Perrone-Filardi, S Paolillo, P Agostoni… - European Journal of …, 2022 - europepmc.org
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
[HTML][HTML] Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan …
P Perrone-Filardi, S Paolillo, P Agostoni… - European Journal of …, 2022 - ejinme.com
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position …
P Perrone-Filardi, S Paolillo, P Agostoni… - EUROPEAN JOURNAL …, 2022 - air.unimi.it
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
[引用][C] Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan …
P Perrone-Filardi, S Paolillo, P Agostoni… - EUROPEAN JOURNAL …, 2022 - iris.unicz.it
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy,
mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian …
mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian …
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position …
P Perrone-Filardi, S Paolillo, P Agostoni… - EUROPEAN …, 2022 - research.unipd.it
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position …
P Perrone-Filardi, S Paolillo, P Agostoni… - EUROPEAN JOURNAL …, 2022 - arts.units.it
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position …
P Perrone-Filardi, S Paolillo, P Agostoni… - EUROPEAN JOURNAL …, 2022 - iris.unibs.it
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position …
P Perrone-Filardi, S Paolillo, P Agostoni… - EUROPEAN JOURNAL …, 2022 - iris.unina.it
: Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position …
P Perrone-Filardi, S Paolillo, P Agostoni… - EUROPEAN …, 2022 - boa.unimib.it
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …